1. Temel SG, Giray A, Karakas B, et al. RAB25 confers resistance to chemotherapy by altering mitochondrial apoptosis signaling in ovarian cancer cells [published online ahead of print, 2020 Sep 8]. Apoptosis. 2020;10.1007/s10495-020-01635-z. doi:10.1007/s10495-020-01635-z
2. Kilic-Kurt Z, Aka Y, Kutuk O. Novel pyrrolopyrimidine derivatives induce p53-independent apoptosis via the mitochondrial pathway in colon cancer cells [published online ahead of print, 2020 Aug 28]. Chem Biol Interact. 2020;109236. doi:10.1016/j.cbi.2020.109236
3. Kutuk MO, Tufan E, Gokcen C, et al. Cytokine expression profiles in Autism spectrum disorder: A multi-center study from Turkey [published online ahead of print, 2020 Jun 18]. Cytokine. 2020;133:155152. doi:10.1016/j.cyto.2020.155152
4. Kutuk MO, Tufan AE, Kilicaslan F, Mutluer T, Gokcen C, Karadag M, Yektas C, Kandemir H, Buber A, Guler Aksu G, Topal Z, Giray A, Celik F, Acikbas U, Kutuk O. Novel inflammatory targets for immunotherapies in pediatric patients with trichotillomania. Immunobiology. 2020 Feb 26:151913. doi: 10.1016/j.imbio.2020.151913. 
5. Timucin AC, Basaga H, Kutuk O. Selective targeting of antiapoptotic BCL-2 proteins in cancer. Med Res Rev. 39:146-175, 2019. doi:10.1002/med.21516
6. Temel ŞG, Karakaş B, Şeker Ü, et al. A novel homozygous nonsense mutation in CAST associated with PLACK syndrome. Cell Tissue Res. 378:267-277, 2019. doi:10.1007/s00441-019-03077-9
7. Kilic-Kurt Z, Bakar-Ates F, Aka Y, Kutuk O. Design, synthesis and in vitro apoptotic mechanism of novel pyrrolopyrimidine derivatives. Bioorg Chem. 83:511-519, 2019. doi: 10.1016/j.bioorg.2018.10.060. 
8. Kutuk MO, Guler G,  Tufan AE, Sungur MA, Topal Z, Kutuk O. Evaluating clonidine response in children and adolescents with attention-deficit/hyperactivity disorder. AIMS Med. Sci. 5: 348–356, 2018. 
9. Turkgenc B, Sanlidag B, Eker A, Giray A, Kutuk O, Yakicier C, Tolun A, Temel SG. STUB1 polyadenylation signal variant AACAAA does not affect polyadenylation but decreases STUB1 translation causing SCAR16. Hum Mutat. 39:1344-1348, 2018. doi: 10.1002/humu.23601. 
10. Kutuk MO, Tufan AE, Guler G, Yalin OO, Altintas E, Bag HG, Uluduz D, Toros F, Aytan N, Kutuk O, Ozge A. Migraine and associated comorbidities are three times more frequent in children with ADHD and their mothers. Brain Dev. 40:857-864, 2018. doi: 10.1016/j.braindev.2018.06.001. 
11. Kale J, Kutuk O, Brito GC, Andrews TS, Leber B, Letai A, Andrews DW.  Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance. EMBO Rep. 19, e45235, 2018. doi: 10.15252/embr.201745235. 
12. Kilic-Kurt Z, Bakar-Ates F, Karakas B, Kutuk O. Cytotoxic and Apoptotic Effects of Novel Pyrrolo[2,3-d]Pyrimidine Derivatives Containing Urea Moieties on Cancer Cell Lines. Anticancer Agents Med Chem. 2018;18(9):1303-1312. doi: 10.2174/1871520618666180605082026. PMID: 29866023.
13. Karakas B, Ozmay Y, Basaga H, Gul O, Kutuk O. Distinct apoptotic blocks mediate resistance to panHER inhibitors in HER2+ breast cancer cells. Biochim Biophys Acta Mol Cell Res. , 1865:1073-1087, 2018. https://doi.org/10.1016/j.bbamcr.2018.05.002
14. Saatci Ö, Borgoni S, Akbulut Ö, Durmuş S, Raza U, Eyüpoğlu E, Alkan C, Akyol A, Kütük Ö, Wiemann S, Şahin Ö. Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer. Oncogene,17:2251-2269, 2018. doi: 10.1038/s41388-017-0108-9
15. Kutuk MO, Altintas E, Tufan AE, Guler G, Aslan B, Aytan N, Kutuk O. Developmental delays and psychiatric diagnoses are elevated in offspring staying in prisons with their mothers. Sci Rep., 8: 1856, 2018. doi: 10.1038/s41598-018-20263-x
16. Acikbas U, Kutuk MO, Tufan AE, Kutuk O, Seddigh SH, Mahboobi H. Effects of childhood cancer on family life and child with cancer. J Med Res Healthc., 2:122-133, 2017.
17. Kutuk MO, Guler G, Tufan AE, Kutuk O. Hiccup Due to Aripiprazole Plus Methylphenidate Treatment in an Adolescent with Attention Deficit and Hyperactivity Disorder and Conduct Disorder: A Case Report. Clin Psychopharmacol Neurosci., 15:410-412, 2017.
18. Kutuk O, Aytan N, Karakas B, Kurt AG, Acikbas U, Temel SG, Basaga H. Biphasic ROS production, p53 and BIK dictate the mode of cell death in response to DNA damage in colon cancer cells. PLoS One, 12:e0182809, 2017.
19. Bodur C, Kutuk O, Karsli-Uzunbas G, Isimjan TT, Harrison P, Basaga H. Pramanicin Analog Induces Apoptosis in Human Colon Cancer Cells: Critical Roles for Bcl-2, Bim, and p38 MAPK Signaling. PLoS One, 8:e56369, 2013.
20. Timucin C, Gul O, Kutuk O, Basaga H. Antibody array-based immunosensor for detecting cardiovascular disease risk markers. J Immunoassay Immunochem., 33:275-290, 2012. 
21. Bodur C, Kutuk O, Tezil T, Basaga H. Inactivation of Bcl-2 through IκB kinase (IKK)-dependent phosphorylation mediates apoptosis upon exposure to 4-hydroxynonenal (HNE).  J Cell Physiol., 227: 3556-3565, 2012.    
22. Tezil T, Bodur C, Kutuk O, Basaga H. IKK-β mediates chemoresistance by sequestering FOXO3; A critical factor for cell survival and death. Cell Signal., 24:1361-1368, 2012. 
23. Kutuk O, Temel SG, Tolunay S, Basaga H. Aven blocks DNA damage-induced apoptosis by stabilising Bcl-xL. Eur J Cancer, 46:2494-2505, 2010.
24. Kutuk O, Letai A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ., 17:1624-1635, 2010.
25. Kutuk O, Arisan ED, Tezil T, Shoshan MC, Basaga H. Cisplatin overcomes Bcl-2-mediated resistance to apoptosis via preferential engagement of Bak: critical role of Noxa-mediated lipid peroxidation. Carcinogenesis, 30:1517-1527, 2009.
26. Hernlund E, Kutuk O, Basaga H, Linder S, Panaretakis T, Shoshan M. Cisplatin-induced nitrosylation of p53 prevents its mitochondrial translocation. Free Radic Biol Med., 46:1607-1613, 2009. 
27. Arisan ED, Kutuk O, Tezil T, Bodur C, Telci D, Basaga H. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat., 119:271-281, 2010.
28. Kutuk O, Letai A.  Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res., 68:7985-7994, 2008.
29. Kutuk O, Letai A.  Regulation of Bcl-2 family proteins by posttranslational modifications. Curr Mol Med., 8:102-118, 2008. 
30. Gul O, Basaga H, Kutuk O. Apoptotic blocks and chemotherapy resistance: strategies to identify Bcl-2 protein signatures. Brief Funct Genomic Proteomic., 7:27-34, 2008.    
31. Kutuk O, Basaga H.  Apoptosis signalling by 4-hydroxynonenal: a role for JNK-c-Jun/AP-1 pathway. Redox Rep., 12:30-34, 2007. 
32. Arslan, MA, Kutuk O, Basaga H.  Protein Kinases as Drug Targets in Cancer, Curr Cancer Drug Targets, 6: 623-634, 2006.
33. Kutuk O, Basaga H.  Bcl-2 protein family: implications in vascular apoptosis and atherosclerosis. Apoptosis, 11: 1661-1675, 2006.
34. Kutuk O, Poli G, Basaga H.  Resveratrol protects against 4-hydroxynonenal-induced apoptosis by blocking JNK and c-JUN/AP-1 signaling. Toxicol Sci., 90: 120-132, 2006.
35. Kutuk O, Pedrech A, Harrison P, Basaga H. Pramanicin induces apoptosis in Jurkat leukemia cells: a role for JNK, p38 and caspase activation. Apoptosis, 10: 597-609, 2005.
36. Kutuk O, Adli M, Poli G, Basaga H. Resveratrol protects against 4-HNE induced oxidative stress and apoptosis in Swiss 3T3 fibroblasts. Biofactors, 20: 1-10, 2004.
37. Kutuk O, Basaga H.  Aspirin inhibits TNFa- and IL-1-induced NF-kB activation and sensitizes HeLa cells to apoptosis. Cytokine, 25:  229-237, 2004.
38. Kutuk O, Basaga H. Inflammation meets oxidation: NF-kB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med., 9: 549-557, 2003.
39. Kutuk O, Basaga H.  Aspirin prevents apoptosis and NF-kB activation induced by H2O2 in HeLa cells. Free Radic Res., 37: 1267-1276, 2003.